

# ValÃ©rie Boige

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6136506/publications.pdf>

Version: 2024-02-01

29  
papers

765  
citations

687220

13  
h-index

610775

24  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1505  
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: Lipiodol vs. drug-eluting beads. <i>Journal of Hepatology</i> , 2012, 56, 609-617.	1.8	161
2	Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4007-4007.	0.8	123
3	Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. <i>European Journal of Cancer</i> , 2017, 87, 122-130.	1.3	120
4	Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). <i>Journal of Clinical Oncology</i> , 2018, 36, 674-681.	0.8	70
5	Systemic treatment of advanced hepatocellular carcinoma: From disillusion to new horizons. <i>European Journal of Cancer</i> , 2015, 51, 327-339.	1.3	63
6	Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 3640-3646.	0.7	25
7	Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4768-4780.	3.2	25
8	The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. <i>EBioMedicine</i> , 2019, 46, 94-104.	2.7	24
9	Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: What survival can we expect?. <i>European Journal of Cancer</i> , 2018, 100, 94-103.	1.3	20
10	Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101590.	0.7	17
11	Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020, 137, 117-126.	1.3	16
12	Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies. <i>Cancer Treatment Reviews</i> , 2021, 97, 102202.	3.4	14
13	FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9 " FFCD 0802). <i>Digestive and Liver Disease</i> , 2015, 47, 271-272.	0.4	13
14	Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK). <i>Digestive and Liver Disease</i> , 2018, 50, 305-307.	0.4	13
15	Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position. <i>European Journal of Cancer</i> , 2020, 135, 103-112.	1.3	11
16	Prognostic Value of Sterilized Lymph Nodes After Preoperative Chemoradiotherapy for Patients with ypN0 Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 1304-1311.	0.7	9
17	Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27). <i>Clinical Colorectal Cancer</i> , 2020, 19, 301-310.e1.	1.0	9
18	Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy " a randomized phase II study - SULTAN UCCI 30/PRODIGE 53 (NCT03164655)- study protocol. <i>BMC Cancer</i> , 2020, 20, 74.	1.1	9

#	ARTICLE	IF	CITATIONS
19	Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. <i>Digestive and Liver Disease</i> , 2016, 48, 1498-1502.	0.4	8
20	First-line treatment in metastatic colorectal cancer: Important or crucial?. <i>European Journal of Cancer</i> , 2017, 84, 363-366.	1.3	4
21	Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial. <i>British Journal of Cancer</i> , 2020, 122, 957-962.	2.9	4
22	Hepatic arterial infusion of chemotherapy as an option in a multimodal treatment of metastatic squamous cell carcinoma of the anus. <i>European Journal of Cancer</i> , 2021, 142, 147-149.	1.3	2
23	Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients (pts): A meta-analysis of individual pts data (IPD) from three phase III studies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3550-3550.	0.8	1
24	Hepatic Resection for Extrahepatic Metastatic Disease: When Is It Reasonable?. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 78-83.	1.0	0
25	Reply to M. Mo et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2452-2453.	0.8	0
26	Express study: A trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS3159-TPS3159.	0.8	0
27	PRODIGE 53-UCGI 30 (SULTAN): A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only colorectal metastases considered still non resectable after at least two months of systemic induction chemotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS3619-TPS3619.	0.8	0
28	Role of precision medicine for patients with advanced biliary tract cancers.. <i>Journal of Clinical Oncology</i> , 2020, 38, 552-552.	0.8	0
29	Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers: Results of the FOLFA randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3555-3555.	0.8	0